Jiangchuan Macrolide Facility Construction Completed

CHENGDU, China, Jan. 27, 2011 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced the completion of the construction of its Jiangchuan macrolide facility (JCM) at Xinjin Industrial Development Area, near Chengdu, China.

JCM is designed to produce the Phase I annual capacity of 240 ton, expandable to 500 ton total Phase II capacity and 900 ton total Phase III capacity of international standard Azithromycin active pharmaceutical ingredient (API) for both domestic and international market. JCM holds both macrolide API production license from China's State Food and Drug Administration (SFDA, www.sfda.gov.cn) and related business licenses from the Industry and Commerce Bureau and Tax department. The completion of Phase I 240 ton capacity manufacturing facility will be followed by the SFDA's GMP certification.

TPI anticipates meaningful revenue contribution from JCM in the current fiscal year 2011.

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI manufactures and markets a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. TPI currently has a pipeline of 10 products pending SFDA approval targeting cardiovascular conditions, women's health, immune system and respiratory disorders. TPI has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about TPI, please visit http://www.tianyinpharma.com.

About Azithromycin

Azithromycin inhibits the growth of bacteria by interfering with their protein synthesis via binding to the 50S subunit of the bacterial ribosome, and consequently inhibiting mRNA translation. Azithromycin has been most effective against a broad spectrum of microorganisms such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Neisseria gonorrhoeae, Chlamydia pneumonia, Chlamydia trachomatis, Mycoplasma pneumonia, Helicobacter pylori, Salmonella typhi and Mycobacterium avium intracellulare. Azithromycin is one of the best selling antibiotics in the world and is included in the Essential Drug List (EDL) of China.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.